MGTA News and Press, Magenta Therapeutics Inc. From 12/12/22

– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory...

CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and we...

Magenta Therapeutics press release ( NASDAQ: MGTA ): Q3 GAAP EPS of -$0.27 beats by $0.03 . Cash, cash equivalents and marketable securities as of September 30, 2022, were $128.3 million, compared to $176.9 million as of December 31, 2021. For further details see...

– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presenta...

– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism – – Poster presentation of data from a MGTA-117 non-human primate study that has provided predictive modeling of bi...

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Cred...

Goldman Sachs has downgraded Magenta Therapeutics ( NASDAQ: MGTA ) from buy to neutral due to a lack of proof-of-concept generating events for one of its lead programs, MGTA-117. The firm kept its $2 price target (~3% upside based on Wednesday's close). Shares are down...

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelle...

Magenta Therapeutics press release ( NASDAQ: MGTA ): Q2 GAAP EPS of -$0.29 beats by $0.06 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $139.4 million For further details see: Magenta Therapeutics GAAP EPS of -$0.29 beats by $0....

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will participate in a Ge...